MediGene (ETR:MDG1) received a €17.00 ($19.77) target price from investment analysts at Baader Bank in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the stock. Baader Bank’s price target suggests a potential upside of 84.78% from the company’s previous close.
Separately, Independent Research set a €15.50 ($18.02) target price on MediGene and gave the stock a “neutral” rating in a research note on Friday, August 10th.
Shares of MDG1 opened at €9.20 ($10.70) on Monday. MediGene has a 12 month low of €8.53 ($9.92) and a 12 month high of €19.27 ($22.41).
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
See Also: Understanding Market Liquidity
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.